benserazide has been researched along with Anochlesia in 11 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mice developed catalepsy after 3 weeks on the LCa/Mg diet." | 1.39 | Combined low calcium and lack magnesium is a risk factor for motor deficit in mice. ( Nakagawasai, O; Nemoto, W; Sato, S; Tadano, T; Tan-no, K; Taniguchi, R; Yamadera, F; Yaoita, F, 2013) |
| "KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i." | 1.29 | KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. ( Kanda, T; Nakamura, J; Shimada, J; Shiozaki, S; Suzuki, F, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gołembiowska, K | 1 |
| Dziubina, A | 1 |
| Kowalska, M | 1 |
| Kamińska, K | 1 |
| Taniguchi, R | 1 |
| Nakagawasai, O | 1 |
| Tan-no, K | 1 |
| Yamadera, F | 1 |
| Nemoto, W | 1 |
| Sato, S | 1 |
| Yaoita, F | 1 |
| Tadano, T | 1 |
| Eltayb, A | 1 |
| Wadenberg, ML | 2 |
| Svensson, TH | 1 |
| Himori, N | 2 |
| Mishima, K | 2 |
| Kanda, T | 1 |
| Shiozaki, S | 1 |
| Shimada, J | 1 |
| Suzuki, F | 1 |
| Nakamura, J | 1 |
| Tanaka, Y | 1 |
| Kurasawa, M | 1 |
| Akaike, N | 1 |
| Verhagen-Kamerbeek, WD | 1 |
| Hazemeijer, I | 1 |
| Korf, J | 1 |
| Lakke, JP | 1 |
| Ahlenius, S | 1 |
| Bhattacharya, SK | 1 |
| Parmar, SS | 1 |
| Aizenstein, ML | 1 |
| Scavone, C | 1 |
| Steinschreiber, S | 1 |
| de-Lucia, R | 1 |
| Cashin, CH | 1 |
| Sutton, S | 1 |
11 other studies available for benserazide and Anochlesia
| Article | Year |
|---|---|
Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Area Under Curve; Benser | 2009 |
Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Bromocriptine; Calcium; Catalepsy; Dopamine | 2013 |
Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa.
Topics: Analysis of Variance; Animals; Avoidance Learning; Benserazide; Catalepsy; Dopamine; Dopamine Agents | 2005 |
The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benserazide; Benzophenones; Catalepsy; Catechol O-Methyltransf | 1994 |
KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.
Topics: Adenosine; Administration, Oral; Animals; Antihypertensive Agents; Benserazide; Catalepsy; Dose-Resp | 1994 |
3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse.
Topics: Animals; Benserazide; Catalepsy; Drug Combinations; Haloperidol; Levodopa; Male; Mice; Motor Activit | 1994 |
Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Catalepsy; Catech | 1993 |
Antagonism by the 5-HT2A/C receptor agonist DOI of raclopride-induced catalepsy in the rat.
Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Benserazide; Benzazepines; Catalepsy; Dopamine Agents; D | 1995 |
Stress by restraining potentiates morphine catalepsy in rats.
Topics: 5,6-Dihydroxytryptamine; Animals; Benserazide; Catalepsy; Diclofenac; Ditiocarb; Drug Interactions; | 1985 |
Differential changes in dopaminergic receptor sensitivity induced by agonist drugs.
Topics: Animals; Apomorphine; Benserazide; Brain Chemistry; Catalepsy; Drug Therapy, Combination; Haloperido | 1985 |
The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine.
Topics: Amantadine; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Benztropine; Brain | 1973 |